In addition, the trial included only three patients with EGFR mutations and excluded patients with ALK translocations, so the study findings might not offer any insights into patients with EGFR mutations or ALK translocations in their tumours, who are known to have a limited response to immunotherapy.39 The gene discussed is ALK; the disease is neoplasm.